Inverness Medical Innovations Announces Fourth Quarter 20...(n-processresearch and development acquir...)

Date:2/20/2008

n-process research and development acquired in connection with our acquisition of Diamics, $5.2 million of restructuring charges, $5.3 million of stock-based compensation expense, a $0.8 million charge related to the write-up to fair market value of inventory acquired in connection with the Cholestech and HemoSense acquisitions, and an unrealized foreign currency loss of $3.9 million associated with a cash escrow established in connection with the acquisition of BBI Holdings Plc. GAAP results for the fourth quarter of 2006 include amortization of $5.4 million, a $1.2 million restructuring charge, and $1.6 million of non-cash stock-based compensation expense. These amounts, net of tax, have been excluded from the adjusted cash basis net income per common share for the respective quarters.

A detailed reconciliation of the Company's adjusted cash basis net income, which is a non-GAAP financial measure, to net loss under GAAP, as well as a discussion regarding this non-GAAP financial measure, is included in the schedules to this press release.

The Company will host a conference call beginning at 10:00 a.m. (Eastern Time) today, February 20, 2008, to discuss these results as well as other corporate matters. During the conference call, the Company may answer questions concerning business and financial developments and trends and other business and financial matters. The Company's responses to these questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been previously disclosed.

The conference call can be accessed by dialing 973-582-2700 (domestic and international), an access code is not required, or via a link on the Inverness website at http://www.invernessmedical.com. It is also available via link at http://audioevent.mshow.com/342025/ using Real Player or
'/>"/>

SOURCE Inverness Medical Innovations Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
2. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
3. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
4. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
7. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
8. Inverness - Chemogen Establish Exclusive License for TB Antibodies
9. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
10. B-Line Medical and Immersion Medical Announce Partnership
11. MIT researcher addresses biomedical engineering challenges